Sign In
Buy LNTH
$99.64
-1.36 (-1.35%)
At Close: Jul 31, 2026
Dimensional Fund Advisors LP Sells 35,893 Shares of Lantheus Holdings, Inc. $LNTH
03:39am, Wednesday, 29'th Jul 2026
Dimensional Fund Advisors LP trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) by 2.5% during the first quarter, according to its most recent disclosure with the Securities and Exc
Lantheus (NASDAQ:LNTH) versus Terumo (OTCMKTS:TRUMY) Critical Review
01:59am, Sunday, 26'th Jul 2026
Terumo (OTCMKTS:TRUMY - Get Free Report) and Lantheus (NASDAQ: LNTH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the s
Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
08:30am, Thursday, 23'rd Jul 2026
BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday
RadioMedix Appoints Brian A. Markison to Board of Directors
01:13pm, Wednesday, 15'th Jul 2026
Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadershi
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
09:51am, Monday, 29'th Jun 2026
On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.'s (NASDAQ:LNTH) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a
US FDA declines to approve Lantheus' tumor imaging kit
04:12pm, Friday, 26'th Jun 2026
The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related condi
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
04:01pm, Friday, 26'th Jun 2026
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinic
Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:12am, Tuesday, 09'th Jun 2026
Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
08:30am, Wednesday, 03'rd Jun 2026
BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping cli
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
08:00am, Tuesday, 02'nd Jun 2026
BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
08:30am, Wednesday, 27'th May 2026
BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clin
Lantheus weighs potential $7 billion sale, Bloomberg News reports
04:27pm, Friday, 22'nd May 2026
Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that could value it at about $7 billion, Bloombe
Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
08:30am, Thursday, 21'st May 2026
BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a
Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
08:30am, Tuesday, 19'th May 2026
BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight a
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
